M3 Wake Research, a premier network of clinical research sites,
is proud to announce the appointment of two key leaders to its
executive team. Logan Ward, an
experienced multi-site operations leader, joins M3 Wake Research as
Chief Business Officer and Lauri
Befus, a seasoned clinical research professional, assumes
the role of Vice President of Clinical Operations.
RALEIGH,
N.C., July 29, 2024 /PRNewswire-PRWeb/
-- M3 Wake Research, a premier network of clinical research
sites, is proud to announce the appointment of two key leaders to
its executive team. Logan Ward, an
experienced multi-site operations leader, joins M3 Wake Research as
Chief Business Officer and Lauri
Befus, a seasoned clinical research professional, assumes
the role of Vice President of Clinical Operations.
"Their leadership and expertise will
significantly contribute to our mission of advancing healthcare and
bringing new treatments to market," said Aki Tomaru, CEO of M3 USA.
Logan is a versatile executive with a track record of driving
operational and commercial excellence, clinical quality, and
strategic growth. He comes to M3 Wake Research from US Radiology
Specialists where he served as Group President. Prior to that he
was EVP of Clinic Operations at American Vision Partners and held
roles of increasing responsibility in finance, strategy, and
operations during his tenure with DaVita, Inc.
Lauri has a deep background in clinical research, holding
multiple leadership roles across various organizations. Her
expertise spans clinical operations, quality management, and
central services. With a solid foundation in psychology and
neuroscience, Lauri is well equipped to lead clinical operations at
M3 Wake Research.
"We are thrilled to welcome Logan and Lauri to our leadership
team. The addition of Logan and Lauri strengthens our commitment to
excellence and innovation in clinical trials," said Aki Tomaru, CEO of M3 USA. "Their leadership and expertise will
significantly contribute to our mission of advancing healthcare and
bringing new treatments to market."
Logan and Lauri's appointments underscore M3 Wake Research's
commitment to excellence and innovation in clinical trials. Their
leadership will be crucial in advancing the company's mission to
bring novel medications, biologics, and devices to patients through
high-quality clinical research.
About M3 Inc.:
M3 Inc. operates in the US, Asia, and Europe with over 5.8 million physician members
globally via its physician websites such as mdlinx.com, m3.com,
research.m3.com, doctors.net.uk, medigate.net and medlive.cn. M3
Inc. is a publicly traded company on the Tokyo Stock Exchange
(TYO:2413) with subsidiaries in major markets including
USA, UK, Japan, S. Korea, and China. M3 Inc. provides services to healthcare
and the life science industry. In addition to clinical research,
these services include medical education, ethical drug promotion,
market research, job recruitment, and clinic appointment services.
M3 has offices in Tokyo,
Fort Washington, PA, Raleigh, NC, Oxford, London, Paris, Beijing, and Seoul.
About M3 Wake Research: M3 Wake Research operates a nationwide
network of integrated investigational sites committed to excellence
in clinical research. M3 Wake Research has conducted over 9,100
studies, partnering with pharmaceutical and biotech sponsors to
bring new treatments to market. M3 Wake Research combines strategic
volunteer recruitment, rapid trial start-up, and high-quality
clinical trial conduct to ensure successful outcomes for clients
and stakeholders. For more information, visit
www.wakeresearch.com.
Media Contact
Marina Lamitina, M3 Wake
Research, 1 (267) 805-3415, mlamitina@usa.m3.com,
https://wakeresearch.com/
View original content to download
multimedia:https://www.prweb.com/releases/m3-wake-research-announces-key-leadership-appointments-to-drive-operational-excellence-and-growth-302207956.html
SOURCE M3 Wake Research